Physician profile
Robert J Edwards
NPI 1659662575
$5,429.67
in general payments reported to CMS, 2019-2025
36 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,199 · 2020: $966 · 2021: $1,185 · 2022: $622 · 2023: $21.90 · 2024: $293 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,447 · Education: $9.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.26 |
| Education | $9.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,035.44 | 2019-2025 | Ozempic |
| Lilly USA, LLC | $557.54 | 2019-2025 | Kisunla, Amyvid |
| Amgen INC. | $536.45 | 2019-2025 | Evenity, Prolia, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.74 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $338.72 | 2024-2025 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $305.52 | 2019-2022 | |
| Radius Health, INC. | $230.91 | 2025 | Tymlos |
| Janssen Pharmaceuticals, INC | $219.07 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $214.69 | 2020-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $212.28 | 2019-2022 | |
| Abbvie INC. | $199.94 | 2021-2024 | |
| Pfizer INC. | $166.20 | 2019-2024 | |
| Glaxosmithkline, LLC. | $118.54 | 2019-2024 | Arexvy |
| Novartis Pharmaceuticals Corporation | $85.69 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $80.41 | 2025 | Gvoke Hypopen, Recorlev |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.